<DOC>
	<DOC>NCT01964352</DOC>
	<brief_summary>The objective of this study is to assess the efficacy and safety of 12 weeks once daily treatment with orally inhaled tiotropium + olodaterol FDC (delivered by the Respimat inhaler) compared with tiotropium and placebo in patients with COPD.</brief_summary>
	<brief_title>Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Olodaterol</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Inclusion criteria: Diagnosis chronic obstructive pulmonary disease Relatively stable airway obstruction with post FEV1 &gt;=30 and &lt; 80% predicted normal and post FEV1/ FVC &lt; 70% Male or female patients, 40 years of age or more Smoking history more than 10 pack years Exclusion criteria: Significant diseases other than COPD History of asthma COPD exacerbation in previous 3 months Completion of pulmonary rehabilitation program within previous 6 weeks or current participation in pulmonary rehabilitation program. Pregnant or nursing women Patients unable to comply with pulmonary medication restrictions</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>